According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...

A clinical trial to test the effectiveness of a new, plant-based oral drug to treat type 2 diabetes has produced some ...

Medium and high type 2 diabetes (T2D) genetic risks are not associated with an increased risk for atherosclerotic ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

If you're living with type 2 diabetes, you'll want to exercise caution before grabbing an energy drink. Read on to find out ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

Regular alcohol consumption, especially outside of meals, was associated with a reduced risk for type 2 diabetes among both men and women.

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

Berberine ursodeoxycholate, a novel gut-liver metabolic modulator, reduces A1c levels and improves glycemic, cardiometabolic, ...